Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Bone-Metastatic CRPC
NCT01428219Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in castration-resistant prostate cancer (CRPC), sponsored by University of Michigan Rogel Cancer Center. Started Feb 2012; status: terminated.
02
Drugs
cabozantinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01428219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01428219.